Mattke Soeren, Haims Marla C, Ayivi-Guedehoussou Nono, Gillen Emily M, Hunter Lauren E, Klautzer Lisa, Mengistu Tewodaj
Rand Health Q. 2011 Sep 1;1(3):1. eCollection 2011 Fall.
Non-communicable diseases (NCDs) now account for the majority of global morbidity and mortality and are increasingly affecting developing countries whose under-resourced health care systems also have to handle a high burden of infectious disease. To counter the global devastation caused by NCDs, the United Nations General Assembly decided to "set a new global agenda" and convened a high-level meeting on NCDs in September 2011. In connection with this meeting, the authors of this article took a first step toward developing a policy research agenda for improving access to NCD medicines in developing countries, a step that the research-based pharmaceutical industry, in particular, can carry forward as part of broader global efforts to combat NCD. The authors provide a framework for understanding the obstacles to access for NCD medicines, review specific issues to be confronted within each obstacle in the developing world, identify promising ideas for improving access to NCD medicines, and point to several highly promising areas for the research-based pharmaceutical industry to focus on as it develops its NCD policy research program in close collaboration with other key stakeholders.
非传染性疾病（NCDs）目前占全球发病率和死亡率的大多数，并且越来越多地影响着发展中国家，这些国家资源不足的医疗保健系统还必须应对高负担的传染病。为了应对非传染性疾病造成的全球破坏，联合国大会决定“制定一项新的全球议程”，并于2011年9月召开了一次关于非传染性疾病的高级别会议。与本次会议相关，本文作者朝着制定一项政策研究议程迈出了第一步，该议程旨在改善发展中国家获得非传染性疾病药物的机会，这一步骤尤其是以研究为基础的制药行业可以作为抗击非传染性疾病更广泛全球努力的一部分加以推进。作者提供了一个理解非传染性疾病药物获取障碍的框架，审视了发展中世界每个障碍内需要面对的具体问题，确定了改善非传染性疾病药物获取的有前景的想法，并指出了几个极具前景的领域，以供以研究为基础的制药行业在与其他关键利益相关者密切合作制定其非传染性疾病政策研究计划时予以关注。
